4885.T

The company maintains a market price of 962 JPY per share, with a market capitalization of 3,872,121,188 JPY. Its price-to-earnings ratio is 16.05, and its price-to-book ratio is 1.58, indicating a moderate valuation relative to its book value. The company's liquidity position is characterized by a current ratio of 2.48, suggesting a strong ability to meet short-term obligations. However, its free cash flow is negative at -20,836,000 JPY, indicating that the company is spending more on capital expenditures than it is generating in operating cash flow.

In terms of profitability, the company's return on equity is 9.84%, and its return on assets is 4.58%, both of which are below the industry median for pharmaceutical companies. The company's operating income is 351,179,000 JPY, and its net income is 241,277,000 JPY, reflecting a relatively modest profit margin. The company's gross profit is 1,960,317,000 JPY, which is a significant portion of its total revenue of 6,653,028,000 JPY.

The company's revenue is primarily concentrated in a single geographic region, with no disclosed segment breakdown. This lack of diversification may expose the company to regional economic and regulatory risks. The company's total assets amount to 5,264,574,000 JPY, with total liabilities of 2,812,793,000 JPY, resulting in a debt-to-equity ratio of 0.67. The company's long-term debt is 1,647,258,000 JPY, and its cash and equivalents are 1,058,068,000 JPY, indicating a net cash position that is negative after subtracting total debt.

The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The company's capital expenditures are -336,217,000 JPY, indicating a reduction in investment in physical assets. The company's operating cash flow is 215,963,000 JPY, which is a positive sign for its ability to generate cash from operations. However, the company's free cash flow is negative, which may limit its ability to fund future growth initiatives.

The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of concern is the negative net cash position after subtracting total debt, which may impact the company's financial flexibility. The company's dilution potential is low, with no significant changes in shares outstanding between basic and diluted shares. The company's risk assessment does not indicate any significant regulatory or geopolitical risks, but the negative net cash position is a notable concern.

Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's latest financial report does not mention any new product launches, regulatory approvals, or major business developments. The company's financial performance is consistent with its historical trends, with no material changes in revenue or profit margins.